^
    BIOMARKER:

    NBN mutation

    i
    Other names: NBN, Nibrin, Nijmegen Breakage Syndrome 1 (Nibrin), Cell Cycle Regulatory Protein P95, NBS1, NBS, P95, P95 Protein Of The MRE11/RAD50 Complex, Nijmegen Breakage Syndrome Protein 1, AT-V1, AT-V2, ATV
    Entrez ID:
    4683
    Apply
    Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    06/30/2022
    Initiation :
    09/14/2020
    Primary completion :
    11/20/2022
    Completion :
    12/28/2022
    HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • RAD50 • CHEK1 • BARD1 • FANCF • FANCM • NBN • WRN • FANCD2 • FANCC
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • BLM mutation • CHEK1 mutation • NBN mutation • FANCM mutation • CHEK1 expression
    |
    Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • pucotenlimab (HX008) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    06/13/2022
    Initiation :
    09/10/2018
    Primary completion :
    12/01/2022
    Completion :
    05/01/2023
    BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD51D • RAD50 • FANCF • FANCL • FANCI • FANCM • NBN • FANCD2 • FANCG • FANCB • FANCC
    |
    CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation
    |
    Rubraca (rucaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma (NCT03840967)
    Phase 2
    Shadia Jalal, MD
    Recruiting
    Last update posted :
    05/24/2022
    Initiation :
    07/09/2019
    Primary completion :
    11/01/2023
    Completion :
    11/01/2024
    BRCA1 • BRCA2 • ARID1A • CDK12 • RAD51 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • RAD54L • BARD1 • NBN • GEN1
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • NBN mutation
    |
    Zejula (niraparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer (HRPCa-II)
    Phase N/A
    Assistance Publique - Hôpitaux de Paris
    Not yet recruiting
    Last update posted :
    05/17/2022
    Initiation :
    10/01/2022
    Primary completion :
    11/01/2027
    Completion :
    11/01/2027
    TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MSH6 • MLH1 • MSH2 • CDH1 • BRIP1 • CHEK2 • RAD51C • RAD51D • RAD50 • BARD1 • NBN • HOXB13
    |
    BRCA1 mutation • PTEN mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • MSH2 mutation • RAD50 mutation • BARD1 mutation • MRE11A mutation • BLM mutation • MLH3 mutation • NBN mutation
    |
    Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations (NCT05229588)
    Phase 2
    HonorHealth Research Institute
    Not yet recruiting
    Last update posted :
    05/12/2022
    Initiation :
    08/01/2022
    Primary completion :
    08/31/2025
    Completion :
    08/31/2026
    BRCA1 • BRCA2 • PTEN • ARID1A • RAD51 • BRIP1 • CHEK2 • NBN • EMSY • CA 19-9
    |
    BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • BRIP1 mutation • CHEK2 mutation • NBN mutation • RAD51 mutation
    |
    Zepzelca (lurbinectedin) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations (NCT04042831)
    Phase 2
    Academic and Community Cancer Research United
    Recruiting
    Last update posted :
    05/09/2022
    Initiation :
    06/09/2020
    Primary completion :
    09/30/2022
    Completion :
    09/30/2024
    BRCA1 • BRCA2 • PTEN • HRD • ARID1A • RAD51 • BRIP1 • CHEK2 • ATR • BRCA • NBN • EMSY
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • BRIP1 mutation • CHEK2 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation
    |
    Lynparza (olaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    04/12/2022
    Initiation :
    04/01/2022
    Primary completion :
    10/30/2023
    Completion :
    10/30/2024
    BRCA1 • BRCA2 • ATM • POLE • BAP1 • MSH6 • MLH1 • MSH2 • RAD51 • BRIP1 • CHEK2 • FANCA • RAD51C • BRCA • RAD51D • RAD50 • CHEK1 • BARD1 • XRCC2 • NBN • FANCD2 • GEN1
    |
    ATM mutation • BAP1 mutation • BRIP1 mutation • CHEK2 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation • BLM mutation • NBN mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    M6620 (VX-970) in Selected Solid Tumors (NCT03718091)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    04/08/2022
    Initiation :
    01/08/2019
    Primary completion :
    06/01/2020
    Completion :
    07/08/2020
    BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • BARD1 • FANCF • FANCM • NBN • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CDK12 mutation • CCNE1 amplification • ATRX mutation • FBXW7 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation
    |
    berzosertib (M6620) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)
    Phase 2
    Clovis Oncology, Inc.
    Active, not recruiting
    Last update posted :
    03/28/2022
    Initiation :
    11/21/2019
    Primary completion :
    05/01/2022
    Completion :
    06/01/2022
    BRCA1 • BRCA2 • RAD51 • RAD51B • BRIP1 • FANCA • RAD51C • RAD51D • BARD1 • NBN
    |
    BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • NBN mutation • FANCA deletion • RAD51 mutation
    |
    Rubraca (rucaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens (NCT04821141)
    Phase 2b
    University of Kansas Medical Center
    Recruiting
    Last update posted :
    02/15/2022
    Initiation :
    12/14/2021
    Primary completion :
    08/01/2025
    Completion :
    01/31/2026
    BRCA1 • BRCA2 • PTEN • STK11 • NF1 • CDH1 • CHEK2 • NBN
    |
    PTEN mutation • PALB2 mutation • CHEK2 mutation • NBN mutation
    |
    Duavee (conjugated estrogens / bazedoxifene) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Niraparib in Tumors Metastatic to the CNS (NCT04992013)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    01/31/2022
    Initiation :
    01/28/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2026
    BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD50 • RAD54L • BARD1 • XRCC2 • NBN • RAD54B • XRCC3
    |
    BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BAP1 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • MRE11A mutation • RAD54L mutation • NBN mutation
    |
    Zejula (niraparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
    Phase N/A
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    12/15/2021
    Initiation :
    02/12/2020
    Primary completion :
    12/01/2030
    Completion :
    12/01/2040
    TP53 • BRCA1 • BRCA2 • MSH6 • MLH1 • MSH2 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • EPCAM • NBN • HOXB13 • GEN1
    |
    BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • PMS2 mutation • NBN mutation
    |
    Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects (SUKSES-B2)
    Phase 2
    Se-Hoon Lee
    Recruiting
    Last update posted :
    08/25/2021
    Initiation :
    08/23/2021
    Primary completion :
    12/31/2022
    Completion :
    12/31/2022
    BRCA1 • BRCA2 • RAD51 • RAD51B • SLFN11 • RAD51C • BRCA • RAD50 • RAD54L • NBN • RAD52 • RECQL5 • WRN • POU2F3 • RECQL • RECQL4 • RPA1
    |
    BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • MRE11A mutation • RAD54L mutation • BLM mutation • BRCA mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO)
    Phase 2
    Gustave Roussy, Cancer Campus, Grand Paris
    Not yet recruiting
    Last update posted :
    03/03/2021
    Initiation :
    03/01/2021
    Primary completion :
    03/01/2024
    Completion :
    03/01/2027
    HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • RAD51 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • ARID2 • RAD54L • BARD1 • NBN • DRD
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • PBRM1 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Zejula (niraparib) • Jemperli (dostarlimab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations (SUKSES-B)
    Phase 2
    Samsung Medical Center
    Completed
    Last update posted :
    02/18/2021
    Initiation :
    08/01/2016
    Primary completion :
    01/01/2021
    Completion :
    01/01/2021
    BRCA1 • BRCA2 • ATM • RAD51 • RAD51B • RAD51C • RAD50 • RAD54L • NBN • RAD52 • RECQL5 • WRN • RECQL • RECQL4 • RPA1
    |
    BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • MRE11A mutation • RAD54L mutation • BLM mutation • NBN mutation • WRN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation
    |
    Lynparza (olaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)